Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131 I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma-Reference-Cited by-同舟云学术

Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131 I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma

Published:2017-10 Issue:2 Volume:99 Page:468-475
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Campbell Kevin,Karski Erin E.,Olow Aleksandra,Edmondson David A.,Kohlgruber Ayano C.,Coleman Matthew,Haas-Kogan Daphne A.,Matthay Katherine K.,DuBois Steven G.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Radiation

Reference33 articles.

1. Neuroblastoma;Maris;Lancet,2007

2. Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction;Mairs;Br J Cancer,1994

3. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma;DuBois;Nucl Med Biol,2008

4. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults;Polishchuk;Cancer,2011

5. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma;Matthay;J Clin Oncol,2007

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The DNA damage response to radiological imaging: from ROS and γH2AX foci induction to gene expression responses in vivo;Radiation and Environmental Biophysics;2023-06-19

2. The DNA damage response to radiological imaging: from ROS and γH2AX foci induction to gene expression responses in vivo;2023-05-05

3. Modulation of Radiation Biomarkers in a Randomized Phase II Study of 131I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory Neuroblastoma;International Journal of Radiation Oncology*Biology*Physics;2023-04

4. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium;Journal of Clinical Oncology;2021-11-01

5. Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures;Radiation Research;2021-10-21